Key result
Transcatheter aortic valve implantation has seen rapid uptake over 15 years, driving the evolution of new devices aimed at reducing complications like paravalvular leak and pacemaker need.
Highlights the evolution of TAVI devices aimed at reducing complications like paravalvular leak and permanent pacemaker implantation.
Over the last 15 years, we have seen a rapid and exponential uptake of transcatheter aortic valve implantation (TAVI) for the treatment of patients with severe symptomatic aortic stenosis (1). This uptake has also been coupled with the evolution and advancement in transcatheter valve technologies. As such, a number of new TAVI devices have also been marketed, mainly with the aim of diminishing problems faced with first generation devices; notably, smaller delivery systems, less incidence of paravalvular leak (PVL) or need for permanent pacemaker implantation (PPI) and other device- or procedural related complications (2,3).
No takes yet. Share an insight, caveat, or question.
Rodrigo Bagur (2018) conducted a review in severe symptomatic aortic stenosis. Transcatheter aortic valve implantation (TAVI) was evaluated. Transcatheter aortic valve implantation has seen rapid uptake over 15 years, driving the evolution of new devices aimed at reducing complications like paravalvular leak and pacemaker need.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: